Plain-English translation of NCT03776812 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial tested , a new medication designed to block a protein called the glucocorticoid receptor, when combined with a standard chemotherapy drug called . Researchers studied whether adding this new medication to chemotherapy could help women whose ovarian, fallopian tube, or peritoneal cancer had returned and stopped responding to platinum-based treatments. The trial compared three groups: one receiving the medication every day, another receiving it only on chemotherapy days, and a third receiving chemotherapy alone.
Platinum-resistant ovarian cancer is difficult to treat because the cancer no longer responds to standard platinum-based chemotherapy. This trial was designed to see if this medication could boost the effectiveness of chemotherapy and help patients whose cancer had become resistant to previous treatments.
Participants received chemotherapy injections on specific days (Days 1, 8, and 15 of each 28-day cycle) and were randomly assigned to one of three groups: one took the new medication every single day, another took it only around chemotherapy days, and the third took chemotherapy alone. Participants continued treatment until their cancer progressed, side effects became too difficult to manage, or other stopping criteria were met, and they were followed for survival and information about any additional treatments they received afterward.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States